General Pediatric Hospital "Children of Acosta Ñu," San Lorenzo, Central, Paraguay.
Immunology Department, Research Institute for Health Sciences, National University of Asuncion, San Lorenzo, Central, Paraguay.
PLoS One. 2023 Oct 5;18(10):e0292314. doi: 10.1371/journal.pone.0292314. eCollection 2023.
The highly contagious nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), requires rapid diagnostic tests to prevent the virus from spreading within hospitals and communities. Reverse transcription followed by the polymerase chain reaction (RT-PCR) test is the gold standard for detecting SARS-CoV-2 infections but is time-consuming, labor-intensive, and restricted to centralized laboratories. There is a growing need to develop and implement point-of-care and rapid tests for SARS-CoV-2 detection to address these limitations. We aimed to evaluate the performance of BioFire Film Array Respiratory Panel 2.1 (BioFire FA-RP2.1) for SARS-CoV-2 detection in a pediatric hospital setting. The BioFire FA-RP2.1 test provides rapid results and can identify several viral and bacterial infections in a single test. This prospective, cross-sectional, diagnostic accuracy study enrolled participants ranging from 0 to 18 years of age, seeking medical consultation for any reason, who had been in contact with individuals confirmed to have COVID-19 or managed at the hospital for medical or surgical reasons. We employed a systematic sampling technique to ensure a representative sample. The study included 339 participants with a median age of 5 years. The BioFire FA-RP2.1 test detected SARS-CoV-2 in 18.6% of cases, while the reference RT-PCR test in 14% of cases. The BioFire FA-RP2.1 sensitivity and specificity for SARS CoV-2 detection were 98% and 94%, respectively. The positive probability coefficient (LR+) was 18. The agreement between the two tests was 0.80. In addition, the BioFire FA-RP2.1 test detected coinfection with two viruses in 7,6% of cases. The BioFire FA-RP2.1 is a reliable solution to meet pediatric healthcare needs and improve prognosis in the post-pandemic era thanks to its friendly interface and rapid testing process.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)具有高度传染性,是 2019 年冠状病毒病(COVID-19)的病原体,需要快速诊断测试来防止病毒在医院和社区内传播。逆转录聚合酶链反应(RT-PCR)测试是检测 SARS-CoV-2 感染的金标准,但耗时、劳动强度大,并且仅限于集中式实验室。越来越需要开发和实施用于 SARS-CoV-2 检测的即时护理和快速测试,以解决这些限制。我们旨在评估 BioFire Film Array Respiratory Panel 2.1(BioFire FA-RP2.1)在儿科医院环境中检测 SARS-CoV-2 的性能。BioFire FA-RP2.1 测试提供快速结果,并可在单次测试中识别多种病毒和细菌感染。这项前瞻性、横断面、诊断准确性研究纳入了因任何原因寻求医疗咨询、与确诊 COVID-19 患者有过接触或因医疗或手术原因在医院接受治疗的 0 至 18 岁的参与者。我们采用系统抽样技术确保样本具有代表性。该研究包括 339 名参与者,中位年龄为 5 岁。BioFire FA-RP2.1 测试在 18.6%的病例中检测到 SARS-CoV-2,而参考 RT-PCR 测试在 14%的病例中检测到。BioFire FA-RP2.1 检测 SARS-CoV-2 的敏感性和特异性分别为 98%和 94%。阳性概率系数(LR+)为 18。两种测试之间的一致性为 0.80。此外,BioFire FA-RP2.1 测试在 7.6%的病例中检测到两种病毒的合并感染。BioFire FA-RP2.1 测试因其友好的界面和快速的测试过程,是满足儿科医疗保健需求并改善大流行后时代预后的可靠解决方案。